dailypolitical.com
Positivewww.dailypolitical.com ·
Zacks Research Upgrades Lisata Therapeutics Nasdaqlsta to Hold
AnalystHealthDiseasesHealth Nutrition And Populati…
Topic context
This topic has been covered 287732 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers an analyst rating change for a small-cap biotech firm. No concrete commercial mechanism (product pipeline, revenue, cost, supply chain) is discussed. The upgrade to 'hold' reflects neutral sentiment, but no operational or financial impact on the biotech sector is evident.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Lisata Therapeutics (NASDAQ:LSTA) upgraded to 'hold' by Zacks Research on May 20, 2026.
- Stock opened at $3.12, 52-week range $1.81-$5.07, market cap $28.42M.
- Last quarter EPS loss of $0.50; projected EPS -1.09 for current year.
- 8.94% of stock owned by institutional investors.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
economictimes.indiatimes.com